-
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
Tuesday, September 28, 2021 - 8:24am | 350Read More...The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project BioShield contract. Related Link: Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection. The option...
-
Altimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers
Thursday, April 1, 2021 - 8:58am | 247Read More...Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The trial was conducted with...
-
Maxim Analyst Issues Update On Tekmira's Ebola Research Development
Monday, April 13, 2015 - 9:58am | 290Read More...In a report published Monday, Maxim Group analyst Jason Kolbert commented on Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)'s ongoing research into the Ebola virus. Tekmira is part of an international consortium known as the International Severe Acute Respiratory and Emerging Infection Consortium (...
